MX2022013195A - Uso de proteina surfactante d para tratar infecciones virales. - Google Patents
Uso de proteina surfactante d para tratar infecciones virales.Info
- Publication number
- MX2022013195A MX2022013195A MX2022013195A MX2022013195A MX2022013195A MX 2022013195 A MX2022013195 A MX 2022013195A MX 2022013195 A MX2022013195 A MX 2022013195A MX 2022013195 A MX2022013195 A MX 2022013195A MX 2022013195 A MX2022013195 A MX 2022013195A
- Authority
- MX
- Mexico
- Prior art keywords
- surfactant protein
- viral infections
- treat viral
- viral infection
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Algunas modalidades de los métodos y composiciones proporcionadas en la presente se refieren al uso de proteína surfactante D (SP-D) para tratar o mejorar una infección viral en un sujeto. En algunas modalidades, la infección viral comprende un coronavirus, como el coronavirus de síndrome respiratorio agudo grave 2 (SARS-CoV-2). Algunas modalidades incluyen el uso de ciertas formulaciones que comprenden una SP-D humana recombinante (rhSP-D).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063013726P | 2020-04-22 | 2020-04-22 | |
| US202063072354P | 2020-08-31 | 2020-08-31 | |
| PCT/US2021/028207 WO2021216584A1 (en) | 2020-04-22 | 2021-04-20 | Use of surfactant protein d to treat viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013195A true MX2022013195A (es) | 2023-01-05 |
Family
ID=78270057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013195A MX2022013195A (es) | 2020-04-22 | 2021-04-20 | Uso de proteina surfactante d para tratar infecciones virales. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230181697A1 (es) |
| EP (1) | EP4138905A4 (es) |
| JP (1) | JP7798791B2 (es) |
| KR (1) | KR20230019089A (es) |
| AU (1) | AU2021258178A1 (es) |
| BR (1) | BR112022021423A2 (es) |
| CA (1) | CA3180205A1 (es) |
| IL (1) | IL297362A (es) |
| MX (1) | MX2022013195A (es) |
| WO (1) | WO2021216584A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118369582A (zh) * | 2022-01-31 | 2024-07-19 | 积水医疗株式会社 | 包含肺表面活性蛋白的液态组合物和包含所述液态组合物的免疫测定试剂盒以及肺表面活性蛋白的保存稳定性提高方法 |
| WO2024097169A1 (en) * | 2022-11-01 | 2024-05-10 | National Jewish Health | Treatment of coronavirus infections with antimicrobial phospholipid compositions |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030221199A1 (en) * | 1998-10-20 | 2003-11-27 | Whitsett Jeffrey A. | Surfactant protein D for the prevention and diagnosis of pulmonary emphysema |
| US8933032B2 (en) * | 1998-10-20 | 2015-01-13 | Children's Hospital Medical Center | Surfactant protein D for the treatment of disorders associated with lung injury |
| US20120220531A1 (en) * | 2011-02-04 | 2012-08-30 | Cincinnati Children's Hospital Medical Center | Surfactant protein d for the treatment of disorders associated with lung injury |
| US20130216499A1 (en) * | 2012-02-17 | 2013-08-22 | Wenlin Huang | Compositions of recombinant human endostatin adenovirus injections and methods of production |
| NL2011626C2 (en) * | 2013-10-17 | 2015-04-20 | Stichting Tech Wetenschapp | Novel polypeptide and uses thereof. |
| US12491234B2 (en) * | 2018-03-29 | 2025-12-09 | Airway Therapeutics, Inc. | Methods and compositions comprising surfactant protein D (SP-D) |
| WO2020247675A1 (en) * | 2019-06-06 | 2020-12-10 | Spiritus Therapeutics, Inc. | Methods for attenuating viral infection and for treating lung injury |
| KR102205028B1 (ko) * | 2020-03-22 | 2021-01-20 | (주)셀트리온 | 사스-코로나바이러스-2에 중화 활성을 갖는 결합 분자 |
| US11123329B1 (en) * | 2020-03-23 | 2021-09-21 | Vicore Pharma Ab | Use of angiotensin II type 2 receptor agonist |
| CN112481417B (zh) * | 2020-12-24 | 2022-05-27 | 山西大学 | 新冠肺炎病毒分型及突变位点快速检测方法及试剂盒 |
-
2021
- 2021-04-20 BR BR112022021423A patent/BR112022021423A2/pt unknown
- 2021-04-20 EP EP21792923.1A patent/EP4138905A4/en active Pending
- 2021-04-20 AU AU2021258178A patent/AU2021258178A1/en active Pending
- 2021-04-20 WO PCT/US2021/028207 patent/WO2021216584A1/en not_active Ceased
- 2021-04-20 MX MX2022013195A patent/MX2022013195A/es unknown
- 2021-04-20 KR KR1020227040749A patent/KR20230019089A/ko not_active Withdrawn
- 2021-04-20 CA CA3180205A patent/CA3180205A1/en active Pending
- 2021-04-20 JP JP2022564443A patent/JP7798791B2/ja active Active
- 2021-04-20 IL IL297362A patent/IL297362A/en unknown
- 2021-04-20 US US17/920,245 patent/US20230181697A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3180205A1 (en) | 2021-10-28 |
| EP4138905A4 (en) | 2024-04-17 |
| KR20230019089A (ko) | 2023-02-07 |
| EP4138905A1 (en) | 2023-03-01 |
| JP7798791B2 (ja) | 2026-01-14 |
| WO2021216584A1 (en) | 2021-10-28 |
| JP2023523253A (ja) | 2023-06-02 |
| BR112022021423A2 (pt) | 2023-01-03 |
| AU2021258178A1 (en) | 2022-11-17 |
| IL297362A (en) | 2022-12-01 |
| US20230181697A1 (en) | 2023-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022011671A (es) | Vacunas contra el coronavirus y metodos de uso. | |
| CO2022018715A2 (es) | Análogos de nucleósido de 1’-ciano y usos de los mismos | |
| CY1112560T1 (el) | Πνευμονικη μεταφορα των αμινογλυκοσιδων | |
| DE60113851D1 (de) | Bakteriophage mit breitem wirtspektrum | |
| MX2020003473A (es) | Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas. | |
| BR0112962A (pt) | Composições farmacêuticas para o tratamento de condições inflamatórias e ulcerativas dolorosas de maioria das superfìcies epiteliais tais como mucosite, estomatite e sìndrome de behcet | |
| BRPI0411900B8 (pt) | compostos e composições farmacêuticas compreendendo os mesmos | |
| AR113422A2 (es) | Agentes tensioactivos reconstituidos que tienen propiedades mejoradas | |
| HRP20040059B1 (en) | Treatment of nail infections with no | |
| ECSP093601A (es) | Proteínas derivadas del virus del síndrome de mancha blanca y sus usos | |
| HRP20041200B1 (hr) | Kiseli inzulinski pripravci poboljšane postojanosti | |
| TR199903053T2 (xx) | Benzimidazol t�revleri. | |
| CL2008001756A1 (es) | Agente de arn de interferencia (iarn); composicion farmaceutica que lo comprende; y su uso para tratar procesos patologicos mediados al menos en parte por la expresion del canal de sodio epitelial alfa (alfa-enac) | |
| MX2022003758A (es) | Composiciones para el cuidado bucal que comprenden acido beta de lupulo y aminoacido. | |
| MX2022013195A (es) | Uso de proteina surfactante d para tratar infecciones virales. | |
| WO2021236957A3 (en) | Ace2 muteins and methods of using the same | |
| MX2023009921A (es) | Formulaciones de proteinas de fusion ace2-fc. | |
| CY1125375T1 (el) | Ενα λυοφιλοποιημενο φαρμακευτικο σκευασμα και η χρηση του | |
| ECSP066495A (es) | Composiciones y metodos para inhibir la infección por virus de síndrome de punto blanco (wssv) | |
| DOP2024000171A (es) | Compuestos antivirales y métodos de elaboración y uso de los mismos | |
| CO2024011995A2 (es) | Compuestos antivirales y métodos de elaboración y uso de los mismos | |
| BRPI0813619A2 (pt) | peptídeos surfactantes pulmonares sintéticos | |
| ATE399558T1 (de) | Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln | |
| PT1276495E (pt) | Utilizacao de tensioactivo pulmonar recombinante para o tratamento precoce de doencas pulmonares agudas | |
| DK1173194T3 (da) | Rekombinant SP-A til behandlingen eller forebyggelsen af lungeinfektion og -inflammation |